Pharmacokinetic and pharmacodynamic variations of acenocoumarol orally administrated either once or twice daily in patients with deep venous thrombosis

Fundamental and Clinical Pharmacology

Volumn 12, Issue 6, 1998, Pages 631-635

  Mismetti, P ^a   Reynaud, J ^b   Laporte Simitsidis, S ^a   Thijssen, H ^c   Tardy Poncet, B ^b   Tardy, B ^a   Buchmuller, A ^a   Decousus, H ^a  

^a SERVICE DE NEUROLOGIE   (France)

^b HÔPITAL NORD   (France)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Deep vein thrombosis; Oral anticoagulants; Pharmacodynamic; Pharmacokinetic; Vitamin K dependent coagulation factors

Indexed keywords

ACENOCOUMAROL; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; PROTEIN C;

ADULT; AGED; ANTICOAGULATION; ARTICLE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG HALF LIFE; FEMALE; HUMAN; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; STEADY STATE;

EID: 0032293434     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1998.tb00997.x     Document Type: Article

References (16)

1. Beverley P, Oxley A, Brigham K, Cox T, Hamilton PJ. Factor II, VII, IX and X concentrations in patients receiving long term warfarin. J Clin Pathol 1987 ; 40 : 94-8
2. Dalen JE, Hirsh J. Third ACCP consensus conference on antithrombotic therapy. Chest 1992 ; 102 : 303S-550S
3. Fekkes N, De Jonge H, Veltkamp JJ, Bieger R, Loeliger EA. Comparative study on the clinical effect of acenocoumarol (Sintrom®) and Phenprocoumon (Marcoumar®) in myocardial infarction and angina pectoris. Acta Med Scand 1971 ; 190 : 535-40
4. Fiessinger JN, Vitoux JF, Roneato M, Delliger A, Dizien O, Aiach M. Variations of Prothrombin Time, Factor VII and Protein C with a single daily dose of Acenocomarol. Haemostasis 1989 ; 19 : 138-41
5. Gallop PM, Lian JB, Hauschka PV. Carboxylated calcium-binding proteins and vitamin K. N Engl J Med 1980 ; 302 : 1460-6
6. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinetic 1986 ; 11 : 483-504
7. Kelly JG, O'Malley KO. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinetic 1979 ; 4 : 1-15
8. Landefeld CS, Anderson PA. Guideline-based consultation to prevent anticoagulant-related bleeding. A randomized, controlled trial in a teaching hospital. Ann Int Med 1992 ; 116 : 829-37
9. Lind SE, Callas PW, Golden RA, Joyner KA, Ortel TL. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coag Fibrinol 1997 ; 1 : 48-53
10. Loeliger EA, Van Der Esch B, Mattern MJ, Den Brabander ASA. Behaviour of factors II, VII, IX and X during long-term treatment with Coumarin. Thromb Haemost 1963 ; 9 : 74-89
11. Ma X, Beguin S, Hemker HC. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemost 1989 ; 62 : 788-91
12. Thijssen HHW, Baars LG. Active metabolites of acenocoumarol. Do they contribute to the therapeutic effect? Br J Clin Pharmacol 1983 ; 16 : 491-6
13. Thijssen HHW, Hemker HC. Oral anticoagulant therapy: which anticoagulant. NTvG 1984 ; 128 : 1559-63
14. Thijssen HHW, Hamulya K, Willigers H. 4-Hydroxycoumarin oral anticoagulants: pharmacokinetics-response relationship. Thromb Haemost 1988 ; 60 : 35-8
15. Van Der Meer FJ, Rosendaal FR, Vanderbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993 ; 153 : 1557-62
16. Williams WJ. Life span of plasma coagulation factors. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds. Hematology. New York: McGraw Hill; 1983. p 1230-5